Deals
While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A list, including a zombie buyout and a bidding war. And no, we’re not talking about Metsera.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Days after reaching a tentative agreement with a majority of states involved in litigation against the company over its role in the opioid crisis in the United States, Purdue Pharmaceuticals filed Chapter 11 bankruptcy.
SpringWorks Therapeutics, Inc. announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $18.00 per share.
Baxter International Inc., a leading global medical products company, has entered into a definitive agreement to acquire Cheetah Medical, an Israel-based leading provider of non-invasive hemodynamic monitoring technologies with offices in Boston, Massachusetts as well as Tel Aviv, as detailed in the company press release.
Biocrates Life Sciences AG, one of the world’s leading biotech companies in the field of metabolomics, is strategically realigning.
Shares of 10X Genomics surged more than 35% on its first day of trading to close at $52.75, well above its $39 initial price offering starting point.
Silence Therapeutics, PLC announces its unaudited interim results for the half year to 30 June 2019.
The startup’s unique technology allows to halt the development of the short memory impairment that is characteristic of the patients with various neurodegenerative diseases.
Funds will enable company to finalize regulatory process with view to obtaining CE mark for ultra-fast robotized ophthalmology laser
G Protein Coupled Receptor (GPCR) expert will invest up to €3M ($3.3M) to unlock the therapeutic potential of breakthrough asset
Ermium Therapeutics announced a series A funding of €6.3 M with Domain Therapeutics, Kurma Partners, Idinvest, and the SATT Erganeo.